NASDAQ · Biotechnology

KYTX (KYTX) Stock

$7.30 -2.54% NASDAQ: KYTX Healthcare

Valuation

MetricValue
Price$7.30
Market Cap$443.81M
P/E Ratio-2.49
P/B Ratio1.71
P/S Ratio0.00
EPS (TTM)$-3.64
52-Week High$13.67
52-Week Low$2.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.40%
ROA-54.76%
ROCE-73.28%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio7.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$6.0M$7.0M$0$0$0
Operating Profit$-26.0M$-29.0M$-62.0M$-143.0M$-170.0M
Net Profit$-26.0M$-29.0M$-60.0M$-127.0M$-161.0M
EPS$-1.02$-1.12$0.00$-3.33$-3.64
Op Margin-465.8%-418.3%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$85.0M$67.0M$75.0M$305.0M$294.0M
Total Liabilities$132.0M$20.0M$26.0M$38.0M$62.0M
Cash$76.0M$38.0M$35.0M$97.0M$124.0M
Borrowings$6.0M$11.0M$9.0M$8.0M$29.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond Insider Monkey · Jul 9, 2026 Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition GlobeNewswire · Jun 22, 2026 FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · Jun 9, 2026 Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? Motley Fool · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-36.0M$-52.0M$-114.0M$-154.0M
Investing Cash Flow$-3.0M$-15.0M$-9.0M$-163.0M$40.0M
Financing Cash Flow$0$0$-1.0M$-3.0M$0
Net Cash Flow$49.0M$-38.0M$-3.0M$62.0M$27.0M
Free Cash Flow$-23.0M$-37.0M$-53.0M$-116.0M$-154.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-38.82%
Quick Ratio7.75
Interest Coverage—
Return 1Y68.36%
Return 3Y—
Return 5Y—

Ownership

Insiders Held7.10%
Institutions Held74.72%
Institutions Float Held80.43%
Institutional HolderSharesReport Date
GordonMD Global Investments LP4,244,8182026-03-31
Gilead Sciences Inc4,126,1192026-03-31
Bain Capital Life Sciences Investors, LLC3,110,0002026-03-31
AIGH Capital Management LLC2,000,0002026-03-31
Deerfield Management Company, L.P2,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%
CTNM $14.16 +2.16% -6.62 $529.39M 0.00%

About KYTX

KYTX is led by CEO Warner Biddle, employs 112 people, headquartered in US, publicly traded since 2024.

KYTX stock trades at $7.30 with a market capitalization of $443.81M. The stock is valued at a price-to-earnings (P/E) ratio of -2.49, price-to-book of 1.71, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.52 and $13.67, and currently trades 46.6% below its 52-week high.

On profitability, KYTX generates a return on equity (ROE) of -69.40%, return on capital employed of -73.28%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides